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Dual-stimuli responsive injectable microgel/solid
drug nanoparticle nanocomposites for release of
poorly soluble drugs†
Adam R. Town,a Marco Giardiello,a Rohan Gurjar,b Marco Siccardi,b
Michael E. Briggs, c Riaz Akhtard and Tom O. McDonald *a
An in situ forming implant (ISFI) for drug delivery combines the potential to improve therapeutic adher-
ence for patients with simple administration by injection. Herein, we describe the preparation of an inject-
able nanocomposite ISFI composed of thermoresponsive poly(N-isopropylacrylamide) based microgels
and solid drug nanoparticles. Monodisperse poly(N-isopropylacrylamide) or poly(N-isopropylacrylamide-
co-allylamine) microgels were prepared by precipitation polymerisation with mean diameters of approxi-
mately 550 nm at 25 °C. Concentrated dispersions of these microgels displayed dual-stimuli responsive
behaviour, forming shape persistent bulk aggregates in the presence of both salt (at physiological ionic
strength) and at body temperature (above the lower critical solution temperature of the polymer). These
dual-stimuli responsive microgels could be injected into an agarose gel tissue mimic leading to rapid
aggregation of the particles to form a drug depot. Additionally, the microgel particles aggregated in the
presence of other payload nanoparticles (such as dye-containing polystyrene nanoparticles or lopinavir
solid drug nanoparticles) to form nanocomposites with high entrapment eﬃciency of the payload. The
resulting microgel and solid drug nanoparticle nanocomposites displayed sustained drug release for at
least 120 days, with the rate of release tuned by blending microgels of poly(N-isopropylacrylamide) with
poly(N-isopropylacrylamide-co-allylamine) microgels. Cytotoxicity studies revealed that the microgels
were not toxic to MDCK-II cells even at high concentrations. Collectively, these results demonstrate a
novel, easily injectable, nanocomposite ISFI that provides long-term sustained release for poorly water-
soluble drugs without a burst release.
1. Introduction
Medication adherence to long-term therapy is vital in the suc-
cessful treatment of chronic illness. However, data from the
World Health Organization revealed that the average medi-
cation adherence lies at only 50% in developed countries and
even less in the developing world.1 Furthermore, potentially
life threatening conditions can have a low adherence; for
example, patients with diabetes display a mean adherence rate
of only 67.5%.2 One way to achieve higher adherence rates for
chronic conditions is to simplify the drug regimen for the
patient.3 Daily oral doses can be replaced by a long acting
system, which provides a sustained release of drug to maintain
a blood plasma concentration at a therapeutic level. This has
been shown to improve adherence by avoiding issues such as
‘pill fatigue’ and missed doses.4,5 This is particularly the case
for patients with psychological dysfunctions where oral medi-
cation compliance can be less than 40%,6 or patients with
drug addictions where large stocks of tablets cannot be pro-
vided.7,8 Long acting systems can include injectable formu-
lations,9 polymeric implants,10 microspheres,11 mucosal
inserts,12 and topical patches.13 These systems can be signifi-
cantly more convenient for the patient and reduce healthcare
costs by avoiding the eﬀects of poor adherence such as hospi-
tal admissions. Initial implant systems were preformed and
required micro surgery, or later the use of large hypodermic
needles.12 This led to the development of in situ forming
implants (ISFI’s).14,15 These implants consist of an injectable
drug formulation which solidifies after injection into the body,
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c6nr07858c
aDepartment of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD,
UK. E-mail: tomm@liv.ac.uk; Tel: +44 (0)151 795 0524
bDepartment of Molecular and Clinical Pharmacology, University of Liverpool,
Block H, 70 Pembroke Place, Liverpool, L69 3GF, UK
cCentre for Materials Discovery, University of Liverpool, Crown Street, Liverpool,
L69 7ZD, UK
dDepartment of Mechanical, Materials and Aerospace Engineering, School of
Engineering University of Liverpool, George Holt Building, Brownlow Hill, Liverpool,
L69 3GH, UK
6302 | Nanoscale, 2017, 9, 6302–6314 This journal is © The Royal Society of Chemistry 2017
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
M
ar
ch
 2
01
7.
 D
ow
nl
oa
de
d 
on
 2
/1
1/
20
20
 2
:3
6:
25
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal  | View Issue
to form a depot, i.e. a site with a large storage of drug from
which sustained drug release can occur over a long period of
time. A number of ISFI systems have been developed, which
achieve in situ gelation or solidification by diﬀerent methods
such as chemical or physiochemical cross-linking,16,17 solidify-
ing organogels,18 and in situ phase separation.19 ISFIs can
suﬀer from many issues and limitations, and to our knowledge
an ISFI without any has yet to be developed. These include a
large burst release of drug,20 potential toxicity of materials,17
cytotoxicity and inflammation response,10 long-term stability
of the drugs,16 mechanical stability of the depot,21 limit to
injection depth,22 pre-heating before injection,23 and variation
in the shape of the implant formed, which leads to a variation
in the amount of drug released.24
With over 60% of new drug candidates estimated to be
poorly water soluble,25 there is a need for an ISFI that could
deliver poorly soluble drugs with enhanced control of release
rate. One way to increase the solubility of poorly water soluble
drugs is to formulate the drug into solid drug nanoparticles
(SDNs).26–30 These are nanoparticles formed solely of drug and
stabilised by polymers and surfactants. SDNs have already
been demonstrated to increase the bioavailability of drug
when orally dosed.31 SDNs have also previously been demon-
strated as long acting injectable formulations,32 requiring
repeated monthly injections. We hypothesised that the release
rate of drug can be tuned by entrapping SDNs in an ISFI, so
that for potent drugs, the injection frequency can be lowered.
Poly(N-isopropylacrylamide) (PNIPAm) is a well-established
thermoresponsive polymer that can be prepared in the form of
nanoparticles known as microgels.33–38 PNIPAm microgels
swell in response to temperature,39 exhibiting a volume phase
transition temperature (VPTT), which is similar to the lower
critical solution temperature (LCST) of linear PNIPAm.40 Below
the VPTT the polymer exists as hydrophilic particles, with the
network swollen by water molecules. This is due to favourable
hydrogen bonding between the amide units of the PNIPAm
and water.36 Above the VPTT, the polymer–polymer hydrogen
bonding becomes more favourable and the particles de-swell
as they expel solvent, resulting in a dramatic decrease in the
diameter of the particle. PNIPAm microgels typically display
both steric and electrostatic colloidal stability; below the VPTT
the polymer chains extend out into solution and provide steric
stabilisation,39 while the charged chain end (derived from use
of an initiator such as potassium persulfate (KPS)) gives the par-
ticles electrostatic stabilisation.41 Above the VPTT, the electro-
static repulsion between particles provides colloidal stability,
despite the collapse of the chain ends providing steric stabili-
sation.42 However in the presence of salts, such as that of phys-
iological fluid, flocculation occurs as the charges are screened.43
Such behaviour allows dual-stimuli responsive microgels to be
designed. The flocculation of the microgels has previously been
used to both block membrane pores44,45 and release drug.46
We hypothesised that by utilising the dual-stimuli respon-
sive properties of PNIPAm microgels with SDNs we could
produce a nanocomposite ISFI that forms a depot upon injec-
tion into a tissue environment. In the work presented here,
SDNs are combined with a PNIPAm microgel in a liquid for-
mulation which can then be injected into a depot site. Here,
rapid aggregation of the microgel particles entraps the SDNs
in a polymer network, forming a nanocomposite depot for sus-
tained drug release. Premature aggregation in the injection
needle is avoided as the microgels only aggregate in the pres-
ence of both the elevated temperature and salt when they have
left the injection needle (see Fig. 1). In this article, we demon-
strate the following: the eﬃcient entrapment of payload nano-
particles within a nanocomposite; that the rate of drug release
from a nanocomposite containing SDNs can be controlled by
blending microgels with diﬀerent comonomer compositions
and show that such ISFIs display sustained release profiles
exceeding 120 days with very little burst release.
2. Experimental section
2.1 Materials
N-Isopropylacrylamide (NIPAm, Sigma-Aldrich), allylamine
(AlA, Sigma-Aldrich), azobisisobutyronitrile (AIBN, Sigma-
Aldrich) N,N-methylenebis(acrylamide) (BIS, Sigma-Aldrich),
potassium persulfate (KPS, Sigma-Aldrich), oil red O (OR,
Sigma-Aldrich), agarose (Sigma-Aldrich), sodium chloride
(NaCl, Sigma-Aldrich), styrene (Sigma-Aldrich), phosphate
buﬀered saline tablets (PBS, Fischer Scientific), 50% (w/v)
aqueous poly(acrylic acid) (P(AcA), Mˉn = 2000, Sigma-Aldrich),
tetrahydrofuran (THF, Fischer Scientific), ethanol (EtOH,
Fisher Scientific), HPLC grade acetonitrile (MeCN, Fisher
Scientific), dichloromethane (DCM, Sigma-Aldrich), polyvinyl
alcohol (PVA grade 4–88, MW 57–77 000, Sigma-Aldrich),
Kolliphor TPGS (BASF), potassium phosphate monobasic
(KH2PO4, Sigma-Aldrich), orthophosphoric acid solution 50%
(KH2PO4, Sigma-Aldrich), hydrochloric acid 37% (HCl, Fischer
Scientific), anhydrous sodium hydroxide pellets (NaOH,
Sigma-Aldrich), CellTiter-Glo® substrate (Promega), CellTiter-
Glo® buﬀer (Promega), 3-(4,5-dimethylthiazol-2-yl)-2,5-dipheny-
ltetrazolium bromide (MTT, Sigma-Aldrich), dulbecco’s modi-
fied eagle’s medium (DMEM, Sigma-Aldrich), rotenone
(Sigma-Aldrich), Hank’s balanced salt solution (HBSS, Sigma-
Fig. 1 Microgel/solid drug nanoparticle composite ISFI system (A)
microgel/SDN solution loaded into syringe (B) de-swelling of microgel
particles in hypodermic needle above VPTT (C) aggregation of microgel
particles entrapping SDNs at depot site, due to contact with salt.
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Aldrich), MDCK-II cell lines (Sigma-Aldrich), N,N-dimethyl-
formamide (DMF, Sigma-Aldrich), sodium dodecyl sulfate
(SDS, Sigma-Aldrich) were all used as received. The model
drug used was lopinavir (LPV, WuXi PharmaTech). Type I dis-
tilled water obtained from a water purification system had a
resistivity of >18 MΩ cm−1 (PURELAB option R, Veolia).
2.2 Synthesis of PNIPAm microgels
The PNIPAm microgels were synthesised by precipitation poly-
merisation. A summary of the formulation which was used for
each microgel species can be found in Table 1. In a typical syn-
thesis, the NIPAm monomer, AlA comonomer and BIS cross-
linker were dissolved in distilled water (130 mL for PNA-00 and
160 mL for PNA-25) in a 250 ml two-neck round bottom flask
equipped with a reflux condenser. This was then sealed and
nitrogen was bubbled through the aqueous solution for 1 hour
whilst stirring (400 rpm) to remove dissolved oxygen. The solu-
tion was then heated to 60 °C. Separately KPS initiator was dis-
solved in distilled water (3.75 mL for PNA-00 and 10.5 mL for
PNA-25) and degassed with N2 for 1 hour before being trans-
ferred to the flask containing the monomers. The reaction was
maintained under a N2 atmosphere for 4 hours at 60 °C before
being cooled down to room temperature. To remove unreacted
impurities, the microgel suspension was dialysed for 5 days
using 12–14 kDa MWCO dialysis tubing, replacing the distilled
water every 12 hours. The purified suspension was then lyophi-
lised (Virtis Benchtop K with ultra-low temperature condenser)
and sealed for storage.
2.3 Characterisation of PNIPAm microgels and aggregate
material
Characterisation of the microgel dispersions and aggregates
was carried out using dynamic light scattering (DLS), laser
Doppler electrophoresis (LDE), scanning electron microscopy
(SEM), 1H nuclear magnetic resonance (NMR), potentiometric
titration, Atomic force microscopy (AFM) and Fourier trans-
form infrared spectroscopy (FTIR). DLS and LDE was per-
formed using a Malvern Zetasizer Nano ZS (running Malvern
Zetasizer software V7.11) (Malvern Instruments, Malvern, UK)
with 633 nm He–Ne laser and the detector positioned at 173°.
Dialysed samples were diluted to 1 mg mL−1. The Z-average
diameter was recorded in the range (20–50 °C) using a thermal
equilibration time of 600 seconds in 1 cm path length dispos-
able cuvettes. Measurements were repeated in triplicate to give
a mean Z-average diameter and polydispersity index (PdI). Zeta
potential measurements were performed using DTS1070
folded capillary cells (Malvern, UK). The pH of the sample was
measured before performing zeta potential measurements,
and for both samples fell in the range pH 7 ± 0.5. Capillary
cells were flushed with ethanol and water prior to usage. The
zeta potential measurement was made with a minimum of 10
and maximum of 40 runs, and the voltage applied was auto-
matically selected by the software. To prepare the microgel dis-
persions for SEM imaging, the samples were diluted to
0.01 mg mL−1 in distilled water. 50 μL of solution was pipetted
onto a circular cover glass (10 mm diameter) attached to a
carbon adhesive disc on an aluminium SEM specimen stub
(12.5 mm diameter). For SEM images of the aggregated
material, swollen gel was formed in PBS and then adhered to a
coverslip on an SEM stub. This was heated to 37 °C to induce
aggregation. The samples were left to air-dry for 24 hours, fol-
lowed by sputter coating with gold (EMITECH K550X) with a
deposition current of 25 mA for 100 seconds before imaging.
SEM images of the microgel morphology were then obtained
using a Hitachi S-4800 FE-SEM at 3 kV. To record 1H NMR
spectra lyophilised microgel sample was dissolved in D2O at
20 mg mL−1 and analysed on a Bruker 400 MHz spectrometer
(Bruker, MA, USA). The potentiometric titration of PNA-25 was
conducted with a 50 mL aqueous dispersion of PNA-25 at 1
mg mL−1. The sample pH was then lowered below pH 4 using
0.1 M HCl. The sample was then titrated with 0.1 M NaOH at
25 °C ± 0.5 °C under a nitrogen atmosphere. A Hanna
Instruments HI-11310 pH electrode (Hanna Instruments,
Bedfordshire, UK) was used to record the change in pH. To
record FTIR spectra a blank background scan was performed,
followed by a recording of the spectra of lyophilised microgel
ca. 5 mg, which was clamped onto the ATR crystal of a Bruker
alpha platinum ATR (Bruker, Santa Barbara, CA, USA). Atomic
force microscopy (AFM) was carried out using a Bruker
Multimode 8 system (Bruker, Santa Barbara, CA, USA) operated
with ScanAsyst Mode in ambient conditions. All testing was
conducted using a Bruker RTESPA-150 probe with a nominal
radius of 8 nm and a spring constant of 5 N m−1. Each scan
was conducted with a resolution of 256 pixels per line and
with a scan rate of 0.799 Hz. The samples were prepared by
placing a thin layer of swollen gel formed in PBS onto glass
coverslips, which were then incubated at 37 °C in a water satu-
rated atmosphere for 72 hours. The coverslips were then
adhered to 15 mm diameter metal stubs for mounting in the
AFM. The AFM images were analysed oﬀ-line using Bruker
Nanoscope Analysis 1.7 software.
2.4 PNIPAm microgel gelation and aggregation studies
The concentration at which the microgel samples formed a
self-supporting gel was found by first adding 10 mg of material
to 1 mL of phosphate buﬀered saline (PBS) in a glass vial with
an internal diameter of 20 mm. Using the tube inversion
method, the mass of microgel was increased in increments
until the microgel no longer flowed upon inversion of the vial
for 30 seconds. The % (w/w) of water contained in the microgel
at 25 °C is calculated from the mass of freeze dried microgel
and water in the swollen microgel formed from the tube inver-
Table 1 The composition used in microgel synthesis
Sample
NIPAm
(mol%)
AlA
(mol%)
BIS
(mol%)
KPSa
(mol%)
[NIPAm]
(mg mL−1)
PNA-00 94.3 — 3.6 2.1 5.8
PNA-25 70.9 24.8 2.7 1.6 25.0
a KPS dissolved at 20 mg mL−1 in distilled water.
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sion method. After heating to 37 °C the aggregate was separ-
ated from the eluted solvent to determine its mass. The mass
of microgel remains constant, so the diﬀerence in mass is
due to any solvent remaining in the aggregate, allowing the
% (w/w) of water at 37 °C to be calculated.
2.5 Tissue injection simulation
Agarose powder (0.5% (w/w)) was slowly added to a beaker of
PBS whilst stirring, and then weighed, before covering the
beaker with plastic wrap with a hole for ventilation, and
heating to 95 °C for 10 minutes. Hot water was then added to
bring the contents to the original weight. This was then cooled
to 55 °C and cast into pre-warmed vials with an internal dia-
meter of 20 mm. These were then left for 12 hours at 37 °C
before use. PNA-25 at 6.2% and 2.0% (w/w) and PNA-00 at
14.9% and 5.7% (w/w) in distilled water were injected through
a 18G hypodermic needle into 0.5% (w/w) agarose gel at 37 °C.
2.5.1 Polystyrene nanoparticle synthesis and oil red dye
(OR) encapsulation. Polystyrene (PS) nanoparticles were pre-
pared using modifications of a dispersion polymerisation
method in which colloidal stability was provided by p(AcA).47
Briefly, styrene monomer (15.35 mL) was dissolved in ethanol
(26.23 mL) and distilled water (101.05 mL) in a 250 mL two-
neck round bottom flask equipped with a reflux condenser.
50% (w/v) aqueous p(AcA) (2.92 mL) was then added along
with KPS (234 mg) in distilled water (3.32 mL). This was then
sealed and nitrogen was bubbled through the aqueous solu-
tion for 1 hour whilst stirring (400 rpm), to remove dissolved
oxygen. The solution was then heated to 70 °C. The reaction
was maintained under a N2 atmosphere for 24 hours before
being cooled to room temperature. The PS nanoparticle sus-
pension was purified by centrifugation (Thermo Scientific
Heraeus Megafuge 8R centrifuge) at a relative centrifugal force
(RCF) of 10 900 in 50 mL centrifuge tubes for 1 hour, and
washed with distilled water (ca. 50 mL), this process was
repeated twice. OR was encapsulated into the particles by mod-
ifying a previous swelling-diﬀusion technique.48 Firstly, the
aqueous PS suspension (32 mg mL−1, 25 mL) and aqueous
Pluronic F127 (72 mg mL−1, 8.3 mL) were added to a 50 ml
centrifuge tube. This was vortexed at 3000 rpm for 60 seconds
and then left for 24 hours on a tube roller (33 rpm).
Tetrahydrofuran (THF) (16.66 mL, 33% (v/v)) containing oil red
O (OR) (14.7 mg) was added to the suspension, and then vor-
texed at 3000 rpm for 600 seconds, followed by 0.5 hours on a
tube roller (33 rpm). The colloid was then washed five times
with distilled water using a centrifuge (RCF = 10 900, 1 hour)
between washes and then lyophilised (Virtis Benchtop K with
ultra-low temperature condenser). A sample of the PS nano-
particles with encapsulated OR was prepared at a concen-
tration of 0.1 mg mL−1 and was analysed with DLS after syn-
thesis and after lyophilisation.
2.5.2 Polystyrene nanoparticle entrapment study. In a glass
vial with internal diameter 20 mm, 66.6 mg of PNA-25 was
mixed with lyophilised PS nanoparticles of 10, 20 and 40%
(w/w) relative to the microgel. After adding 1 mL of PBS the
dispersion was left for 10 min to allow the lyophilised microgel
to swell. The samples were then vortexed at 300 rpm to mix the
PS nanoparticles through the swollen microgel dispersion.
These samples were then heated (in a water bath) to 37 °C for
1 hour to form shrunken discs of aggregated microgel, with
excess PBS expelled from the discs in the heating process. A
negative control of microgel alone and positive control of PS
particles alone were conducted alongside the samples. 0.2 mL
of solution was removed for UV-visible spectrophotometric
analysis (Thermo Scientific NanoDrop 2000c) with a 1 cm path
length quartz cuvette at a wavelength of 565 nm (λmax for OR).
To determine the concentration of PS nanoparticles a stock
solution of 1 mg mL−1 dispersed in PBS was serially diluted to
form a linear calibration curve of absorbance at 565 nm
against concentration in the range 1–100 μg mL−1.
2.6 Lopinavir (LPV) solid drug nanoparticle (SDN) synthesis
The LPV SDNs were prepared by emulsion-spray-drying as
described by Owen et al.49 Briefly, a stock solution of LPV
(200 mg mL−1 in dichloromethane (DCM)), polyvinyl alcohol
(PVA grade 4–88, MW 57–77 000) (50 mg mL−1 in water),
Kolliphor TPGS (50 mg mL−1 in water) were prepared. Three
stock solutions were mixed in the LPV : PVA : Kolliphor TPGS
ratio of 60 : 192 : 48 (mL) in a 1 : 4 DCM to water mixture.
Emulsification was conducted using a Hielscher UP400S ultra-
sonic processor equipped with a H14 Probe at 100% output
(140 W) for 180 seconds, with immediate spray-drying using a
benchtop spray-dryer (BUCHI Mini-290) with an air-atomizing
nozzle and compressed air as the drying gas. Spray-drying
process conditions: 7 mL min−1 solution flow rate; 65 °C outlet
temperature; 110 °C inlet temperature. Resultant powders were
further dried under vacuum for 48 hours to remove residual
DCM. SDN dispersions result from subsequent powder dis-
persion in water; for DLS characterisation, powders were dis-
persed in distilled water at 2 mg mL−1 (1 mg mL−1 cf. LPV).
2.7 Drug release in phosphate-buﬀer saline (PBS)
The in vitro drug release was performed using adaptations of
the sample and separate method,50 as performed in previous
work.51 The required amount of each lyophilised microgel,
6.24% (w/w) for PNA-25, and 14.90% (w/w) for PNA-00, was dis-
persed to form a swollen self-supporting gel in 1 mL of PBS
(pH 7.4, 0.137 M NaCl and 0.0027 M KCl) in a glass vial of
internal diameter 20 mm. To this 22.2 mg of LPV or 44.4 mg
of LPV SDNs (50% (w/w) loading of LPV) were vortexed to give
22.2 mg of LPV per formulation. These were then heated to
37 °C for 1 hour to form shrunken discs with excess PBS
expelled from the discs in the heating process, this was
removed and used as the first release time point. These discs
were transferred to larger 250 mL glass sample jars with
100 mL of fresh PBS. Subsequent release samples were taken
at pre-determined intervals by removing 100 mL from the
vessel and replacing with 100 mL of fresh PBS at 37 °C to
prevent a saturation limit with a large excess of solvent.
Release vessels were kept at 37 °C ± 0.5 °C in a water bath. The
amount of LPV released was quantified by HPLC analysis.
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2.8 HPLC procedure
The HPLC method is adapted from the method published by
Giovanni Di Perri et al.52 Briefly, HPLC grade acetonitrile
(MeCN) (1.8 mL) was added to each release sample (4.2 mL) to
create 30% (v/v) MeCN samples, followed by filtering through
a 0.45 μm PTFE syringe filter. 40 μL of the solution was
injected into a HPLC-PDA system (PerkinElmer Series 200).
The mobile phase was composed of solvent A (KH2PO4 50 mM
dissolved in HPLC grade water then pH adjusted with H3PO4
to reach pH 3.23) and solvent B (MeCN) with the gradient
reported in Table 2. Chromatographic separation was per-
formed with an Agilent ZORBAX Eclipse Plus 3.5 μm C18
column (100 × 4.6 mm ID, Santa Clara, CA) maintained at
25 °C in a column oven with a solvent flow rate of 0.5
mL min−1 giving a retention time of LPV of 9.6 ± 0.2 min. The
PDA detector was set to 210 nm with a bandwidth of 2 nm.
The concentration of LPV in the samples was calculated
against known standards using the area under the chromato-
gram peaks. Three standards covering the concentration range
of the HPLC method were used to verify the results, and
samples were analysed in duplicate.
2.9 In vitro microgel cytotoxicity study
Cytotoxicity experiments were carried out on MDCK-II cell
lines by MTT and ATP assay (Promega CellTiter-Glo®
Luminescent Cell Viability Assay, Madison, WI). In both assays
cells were seeded on 96-well plates at a density 2 × 104 cells per
well in 100 μL of Dulbecco’s Modified Eagle Medium (DMEM)
and incubated for 24 hours. Ten diﬀerent concentrations of
the microgels were prepared by ten-fold serial dilution with
the media, starting at 10 mg mL−1. A ten-fold serial dilution of
rotenone from 100 µM acted as a positive control, and cells
alone in media as a negative control. Cells were incubated for
72 hours at 37 °C. In the ATP assay the wells were then equili-
brated at room temperature for 30 minutes. 100 μL of Beetle
Luciferin (CellTiter-Glo® Reagent) was added and mixed on an
orbital shaker for 2 minutes to induce cell lysis. After incu-
bation for 10 minutes at room temperature the luminescent
signal was measured using a GENios microplate reader
(TECAN). Samples were repeated in quadruplicate. The back-
ground luminescence of DMEM was subtracted from the
sample luminescence. In the MTT assay after the 72 hour incu-
bation period, 5 mg of MTT was dissolved in 1 mL of hank’s
balanced salt solution (HBSS). 20 μL was added to each well
and incubated for 2 hours, followed by 100 μL of lysis buﬀer
(50% DMF in water containing 20% SDS) for 12 hours. The
absorbance of each well was measured at a wavelength of
560 nm using a GENios microplate reader (TECAN). Samples
were repeated in quadruplicate. The absorbance of DMEM,
and the absorbance of microgel interaction with MTT without
cells present, was subtracted from the sample absorption.
3. Results and discussion
3.1 Preparation and characterisation of PNIPAm microgels
PNIPAm microgels were prepared via precipitation polymeris-
ation before being characterised by dynamic light scattering
(DLS), scanning electron microscopy (SEM), Fourier transform
infrared spectroscopy (FTIR) and potentiometric titration.
When the NIPAm monomer is used at a suﬃciently low con-
centration (5.8 mg mL−1) in aqueous solution, Table 1, narrow
polydispersity microgel particles, PNA-00 (mean Z-average dia-
meter = 567 nm, PdI = 0.24 at 25 °C) were produced, Fig. 2(A)
(i). When the charged comonomer allyl amine (AlA) was intro-
duced at 25 mol% the concentration of NIPAm in the synthesis
could be increased, Table 1, whilst still obtaining monodis-
perse particles of a similar size, as in PNA-25 (mean Z-average
diameter = 547 nm, PdI = 0.11 at 25 °C) Fig. 2(A)(ii). This was
attributed to the comonomer providing electrostatic stabilis-
ation of the particles during synthesis, preventing aggregation
when the concentration of growing particles during synthesis
is increased. SEM images show that discrete monodisperse
particles were formed for both microgel samples PNA-00 and
PNA-25, with a diameter corresponding to the Z-average dia-
meter of the particles above the VPTT measured via DLS
(approximately 250 nm). 1H NMR and FTIR spectra is consist-
ent with previous microgel characterisations, with all proton
signals of PNIPAM accounted for (see ESI Fig. S1†) with a weak
signal detected at 2.81 ppm for the CH2 in the side group of
the polyallylamine repeat unit.53–55 NMR analysis also demon-
strated that all unreacted monomers were removed during
workup of the microgels as no vinyl peaks can be seen in the
range 5.5–6.5 ppm. The FTIR spectra for the microgels were
found to match that of previously studied PNIPAM microgels,
however there was no noticeable diﬀerence between the IR
spectra for PNA-00 and PNA-25. This was likely because the
mol% of comonomer AlA incorporation was low or due to
overlap between the signals for the primary amines of the poly
(allyl amine) repeat unit compared to the signal from the
amides from poly(N-isopropylacrylamide) (see ESI Fig. S2†).36
Due to the lack of clear signals to prove allyl amine inclusion
potentiometric titration was used to quantify the number of
amines present in the sample.38,56,57 This suggests 3.1 mol%
AlA was incorporated into the microgel (see ESI Fig. S3†).
In order to investigate the dual-stimuli responsive pro-
perties of the microgel samples, the Z-average diameter and
zeta potential of the microgels were measured at intervals over
the temperature range 15 to 55 °C for both PNA-00 and
PNA-25. As PNA-00 is heated in water the particles de-swell but
remain colloidally stable, resulting in the dramatic decrease in
Table 2 The solvent gradient used in the HPLC method
Time (min) Solvent A % (v/v) Solvent B % (v/v) Flow (mL min−1)
0.0 70 30 0.5
1.0 70 30 0.5
3.0 30 70 0.5
11.5 30 70 0.5
12.0 70 30 0.5
12.5 70 30 0.5
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Z-average diameter at the VPTT, Fig. 2(B)(i), as first shown by
Pelton et al.58 In the presence of salts at physiological concen-
trations (0.137 M) the particles flocculate as they reach the
VPTT, indicated by the dramatic increase in Z-average diameter
beyond 32 °C.39 The sample containing 25 mol% AlA (PNA-25)
showed the same colloidal stability in water and triggered floc-
culation in PBS, Fig. 2(B)(ii). The salt-responsive flocculation
of the microgels was also investigated with a range of NaCl
concentrations. Increasing the NaCl concentration resulted in
the aggregation temperature decreasing due to the poorer
solvent environment for the PNIPAM. PNA-00 and PNA-25 were
both found to show similar responses, Table 3. Previous work
by Vincent et al. has shown that PNIPAM microgels syn-
thesised with BIS and a sulphate initiator flocculate in NaCl
above a concentration of 0.025 M when raising the tempera-
ture.43 At a low NaCl concentration the interparticle electro-
static repulsion was great enough to prevent flocculation. At
higher concentrations these electrostatic forces are weakened
enough to allow flocculation. Analysis of the zeta potential of
PNA-00 with increasing temperature in water displayed an
initial negative zeta-potential of −12 mV up to 25 °C, attribu-
ted to the KPS providing a negative surface charge on the
microgels through its incorporation at the polymer chain ends.
As the temperature increases above the VPTT the zeta potential
shows a corresponding decrease to >−40 mV as the surface
charge density increases with the decrease in particle surface
area, and the chains ends collapse onto the surface. For
sample PNA-25 the zeta potential was positive, indicating suc-
cessful incorporation of a proportion of the AlA comonomer to
give a cationic charge that counters the anionic charge of the
chain ends. When the particles were heated above their VPTT
the zeta potential increased as the reduction in size resulted in
an increase in charge density. The two microgels show temp-
erature and salt responsive behaviour, with flocculation only
occurring when both the temperature is above the VPTT and
the ionic strength is suﬃcient. This is ideal for triggered aggre-
gation in response to physiological conditions in an ISFI
system.
3.2 PNIPAm microgel aggregate studies
Given the propensity for the microgels to flocculate in a dilute
dispersion, the concentration of the dispersion was increased
to determine whether bulk aggregation on a macroscopic scale
was possible. The relative hydrophilicity of each microgel was
measured by its % (w/w) water content above and below the
VPTT. The concentration (% (w/w)) of PNA-00 and PNA-25 in
Fig. 2 Characterisation of PNA-00 and PNA-25 microgels by dynamic
light scattering, laser Doppler electrophoresis and SEM. (A) SEM images
of the dried microgel particles and DLS size distribution by intensity at
25 °C (i) PNA-00 (ii) PNA-25. (B) Temperature dependence of the hydro-
dynamic diameter in either water or phosphate buﬀered saline (PBS) and
zeta potential of (i) PNA-00 (ii) PNA-025 in water.
Table 3 Microgel ﬂocculation in NaCl
Aggregation temperaturea (°C)
[NaCl] (mol L−1) PNA-00 PNA-25
0.001 — —
0.010 — —
0.100 34 42
1.000 24 24
a Samples heated in 1 °C intervals from 15 to 55 °C. Flocculation indi-
cated by large increase in Z-Ave, as shown in Fig. 2.
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PBS at 25 °C was increased and studied via the tube inversion
method until a gel was formed. The concentration required for
a self-supporting gel was 6.24% (w/w) for PNA-25 and 14.90%
(w/w) for PNA-00. Previous work has shown that PNIPAm
microgels which are polyampholytic in nature swell as the
ionic strength of the solvent increases,59 hence a lower
(% w/w) of PNA-25 is required to form a self-supporting gel.
Upon heating to 37 °C both gels aggregate and expel solvent in
the process. The microgels formed a phase separated disc
shape of aggregated material, due to the cylindrical shape of
the vial used, Fig. 3. The formation of aggregate over time can
also be seen in ESI Fig. S4,† showing that the time for both
samples to form dense aggregates was approximately
90 minutes. The aggregated form of the microgels was seen as
the surface charge of the microgel was not great enough to
form a shrunken gel.60 This process was reversible, after being
held at 37 °C for 1 hour and cooling, the aggregate returned to
a self-supporting gel that re-adsorbed the expelled solvent
within 1 hour. The water content of PNA-00 and PNA-25 were
measured both above and below the VPTT. Below the VPTT the
water content of the samples were 85.1% and 93.8% for
PNA-00 and PNA-25 respectively. The hydrophilic nature of AlA
is independent of temperature,61 hence the sample containing
AlA, PNA-25, remained much more hydrophilic above the
VPTT (at 37 °C) containing 76.8% w/w water while PNA-00 con-
tained only 34.5% water. This diﬀerence in the water content
of the aggregates was reflected in the reduction in volume
when the swollen gel forms an aggregate. The swollen gel of
PNA-00 had a larger percentage reduction in volume than
PNA-25 upon forming an aggregate. This data is summarised
in Table 4. Despite the PNA-00 swollen gel being formed of
14.90% (w/w) microgel, its % reduction in volume upon aggre-
gation was greater than the lower microgel content of 6.24%
(w/w) in the PNA-25 swollen gel. This suggests the aggregate of
PNA-25 contained a greater volume of free space between
aggregated microgel particles, owing to its smaller % volume
reduction upon aggregate formation. The structure of the
aggregates was investigated further via SEM and AFM imaging.
Samples of the PNA-00 and PNA-25 aggregates were dried and
imaged by SEM (shown in Fig. 4A and B respectively). The
PNA-25 aggregate displayed a dense structure with a tendency
to film-form while the PNA-25 aggregate presented a looser
structure in which individual particles could easily be distin-
guished. AFM analysis was then utilised to assess the topo-
graphy of the samples, (Fig. 4C and D for PNA-00 and PNA-25
respectively) these images revealed that PNA-25 presented a
fibrous structure compared to the irregular structure of
PNA-00. The diﬀerences in the topography of the samples are
clearly shown in the 3D representation of the AFM characteris-
ation, Fig. 4E for PNA-00 and Fig. 4F for PNA-25. The surface
of the PNA-25 aggregate was much rougher (roughness (Rq)
value of 267 nm) compared to PNA-00 (Rq value of 182 nm)
and PNA-25 revealed potential pores between the fibres. This
fibrous structure of the PNA-25 aggregates was not expected
and is an aspect for further investigation in the future. The
diﬀerence between the two aggregates explains the higher
water content of PNA-25 due to its greater porosity and may
alter the rate of drug release from the aggregates.
The propensity for the microgels to flocculate in response
to both temperature and salt could be utilised to give a macro-
scopic aggregate at high microgel concentrations. Potentially
the relative hydrophilicity and porosity of the aggregates can
be tuned by mixing PNA-00 and PNA-25 due to their diﬀerent
water content and apparent structural diﬀerences in aggre-
gated form.
Upon injection as an ISFI the swollen gel will be in contact
with interstitial fluid, which contains the metal ions mag-
nesium and calcium as part of a complex mixture of inorganic
salts.62 This inorganic salt composition was simulated by
Hank’s balanced salt solution (HBSS). Therefore, in order to
more closely mimic the ionic environment in vivo the aggrega-
tion of the microgels was assessed in HBSS instead of PBS.
Aggregation was found to occur in HBSS (see ESI Fig. S5†) in a
similar manner to the PBS studies and hence the diﬀerent
metal ions present in HBSS were not found to inhibit the
aggregation process.
3.3 Injection of microgels into tissue mimic
Given that formation of the depot aggregate occurs upon
exposing the concentrated microgels to physiological con-
ditions we next assessed the suitability of injection into tissue.
For this purpose we utilised agarose gel as a subcutaneous
Fig. 3 Images of dual-responsive transition of the microgels in PBS;
from swollen self-supporting gels to bulk aggregates. Microgel samples
as swollen gel (left) and bulk aggregate (right). PNA-00 (top) and
PNA-25 (bottom).
Table 4 Water content of the microgels at 25 °C and 37 °C and change
in volume
Sample
% (w/w) of water
contained within
the sample
% reduction in volume
upon forming aggregatea25 °C 37 °C
PNS-00 85.1 34.5 76
PNA-25 93.8 76.8 66
a The height and diameter of the cylindrical swollen gel and corres-
ponding aggregate were used to calculate the change in volume (see
ESI Fig. 4 for images of the samples).
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tissue mimic63 at 37 °C. The concentrated microgel at ambient
temperature was injected into the tissue mimic through a
hypodermic needle. The sheer thinning properties of PNIPAm
microgels allowed the swollen gel of PNA-00 and PNA-25 to be
injected through a 18G needle. This is followed by rapid aggre-
gation of the particles into a depot. Additionally, depot for-
mation was also possible with a much lower microgel concen-
tration; PNA-25 was injected as a liquid at 2.0% (w/w) and dis-
played the same aggregation behaviour as higher microgel con-
centrations, Fig. 5 (see video in ESI†). The ability to obtain
depot formation at lower concentrations is beneficial as a
liquid is more desirable for ease of formulation with drug and
loading into a syringe for as an ISFI.17 The microgel aggregate
formed a planar depot that is most likely due to the fracturing
of the agarose gel by the hypodermic needle, and the sub-
sequent filling of the void by the microgel outwards along the
fault line.
3.4 Polystyrene nanoparticle entrapment study
An ISFI will ideally display no initial burst release, therefore in
our system as the microgels aggregate they should be able to
rapidly entrap a payload of drug containing nanoparticles with
high entrapment eﬃciency.24 To probe this ability, oil red O
dye-containing polystyrene (PS) nanoparticles were synthesised
Fig. 4 Characterisation of microgel aggregates. (A, B) SEM images, (C, D) AFM images and (E, F) 3D representations of (C, D) respectively. PNA-00
shown in (A, C, E) and PNA-25 in (B, D, F).
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as a model payload which mimics the entrapment of solid
drug nanoparticles. Like solid drug nanoparticles, oil red O
dye-containing PS nanoparticles can form a nanosuspension
in water, and are a similar size, however the oil red O within
the PS particles allows quantification of the amount released
using UV-Vis spectroscopy. Firstly, the PS particles were syn-
thesised using adaptations from a previously published dis-
persion polymerisation method.47 The PS nanoparticles were
then dyed with the hydrophobic dye Oil Red O (OR),48 so that
the release could be quantified at a wavelength of 580 nm
where there is negligible absorbance by any potential PNIPAm
fragments lost from the aggregate. These dye containing par-
ticles will be denoted as PS-OR. The PS colloids were character-
ised using DLS after synthesis and when dispersed into PBS as
PS-OR after dying and lyophilisation (see Table 5). The slightly
larger Z-average diameter after dying can be accounted for by
entrapment of dye. SEM images revealed that monodisperse
particles with spherical morphology were synthesised, (see
ESI, Fig. S6†). Nanocomposites containing PS-OR nano-
particles were then prepared. Firstly, PNA-25 was dispersed at
6.24% (w/w) in PBS to give a swollen gel and then PS-OR
nanoparticles were mixed into the gel at 10, 20 and 40% (w/w)
vs. PNA-25. These samples remained as swollen self-support-
ing gels even with 40% (w/w) PS-OR nanoparticles loaded,
Fig. 6(A)(i).
Upon heating to 37 °C to induce aggregation, the expelled
solvent is visibly colourless, suggesting that PS-OR particles
remained entrapped as a nanocomposite with the microgel
Fig. 6(A)(ii). This burst release behaviour was quantified by
UV-Vis to determine the concentration of PS-OR particles in
the expelled liquid (see ESI, Fig. S7†). This analysis showed
low burst release (<13%) for all samples but that increasing
the concentration of PS-OR nanoparticles led to greater burst
release, Fig. 6(B). This data indicates the microgels are able to
retain the majority of a nanoscale payload distributed through
the nanocomposite as it aggregates from a swollen gel. This is
despite a substantial volume of PBS being expelled from the
polymer network of the contracting microgel particles.
3.5 In vitro release study
To test the release rate of drug from the microgel aggregates
in vitro, formulations were created from the mixing of poorly
water-soluble antiretroviral drug lopinavir (LPV) in its powder
form, or solid drug nanoparticle (SDN) form, into swollen gels
(the diﬀerent formulations are shown in Table 6). LPV is a
potent HIV-specific protease inhibitor which is administered
in combination with ritonavir as a booster and requires daily
oral dosing for life.64,65 We selected LPV as the model hydro-
phobic drug in our study given its very low aqueous solubility
Fig. 5 Image showing injection of PNA-25 through 18G hypodermic
needle into 37 °C agarose gel, followed by aggregation of material at
time points (A) 0 (B) 5 (C) 12 and (D) 19 seconds.
Table 5 PS nanoparticle properties
PS after synthesis PS-OR dispersed in PBS
Z-Average
diameter (nm) PdI
Z-Average
diameter (nm) PdI
802 ± 14 0.05 ± 0.03 821 ± 25 0.05 ± 0.04
Fig. 6 (A) (i) Swollen gel composite of 40% (w/w) PS nanoparticle
loaded into PNA-25 at 25 °C and (ii) aggregation of composite at 37 °C
with entrapment of PS nanoparticles. (B) Percentage of total PS particles
released 1 hour after aggregation of composite.
Table 6 Formulations of microgel-drug for ISFI’s
Formulation
LPV
(mg)
LPV SDNa
(mg)
PNA-00
(mg)
PNA-25
(mg)
% (w/w)
waterb
Free SDN — 44.4 — — —
PNA-25-SDN — 44.4 — 66.6 76.8
PNA-00/25-SDN — 44.4 87.5 33.3 56.4c
PNA-00-SDN — 44.4 175 — 34.5
PNA-25-LPV 22.2 — — 66.6 76.8
a LPV SDNs consist of 50% (w/w) LPV the remainder is 40% PVA and
10% Kolliphor TPGS. b% (w/w) of water in aggregate at 37 °C.
c Calculated from: ∑ amount of water contained in mass of each
microgel, and total mass of microgel in formulation.
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(predicted to be 0.00192 mg mL−1) and on-going evaluation of
LPV SDNs in clinical trial (clinicaltrials.gov reference
NCT02631473). The LPV SDNs had a Z-average diameter of
330 nm and PdI of 0.18 (see ESI Fig. S8†). Swollen gels were
used so that aggregated disk shaped samples formed upon
heating, to simplify sampling release media in the release
experiment (see ESI Fig. S9†). Utilising the large diﬀerence in
the water content and porosity of the PNA-00 and PNA-25
aggregated microgel materials at 37 °C, Table 4, allows the two
microgel samples to be mixed in diﬀerent ratios to tune the
water content of the aggregate. Poorly water soluble drugs have
been shown to have a slower release rate from an insoluble
matrix than more water soluble drug,66 hence we expected the
water content and structure of the aggregates to control the
rate of release of drug. PNA-00 and PNA-25 were used with a
mass of each that gave a self-supporting gel at room tempera-
ture in 1 mL of PBS, and 56.4% (w/w) water in the aggregated
form (denoted as PNA-00/25-SDN), giving an intermediate
water content between that of the two microgels when used
separately. The release of drug into the PBS surrounding the
microgel/SDN nanocomposites was then measured over time
using HPLC. Due to the low saturation concentration of the
drug, the release media was completely removed and replaced
during the release experiment.10 The nanocomposite showed
excellent mechanical stability, remaining in its original shape
over the complete release period. Comparing the release of
LPV from the formulations PNA-25-SDN, PNA-00/25-SDN and
PNA-00-SDN it can be seen that if the depot has a higher
% (w/w) water content the release rate is enhanced, leading to
a larger total cumulative release after 120 days, Fig. 7. This
eﬀectively allows us to tune the release rate from the depot.
Based on the characterisation of the aggregate with SEM and
AFM we speculate that this could be due to the formation of a
more porous structure containing more water, which has been
linked with faster drug release.46 Solute transport from
non-degradable polymeric systems is mainly considered as
diﬀusion driven, with matrix-type devices showing Fickian
diﬀusion.67 We applied the Higuchi model of drug release,68
which describes drug release from a matrix system to our
release data.69 We used the simplified Higuchi model, see
Fig. 7(c).70,71 This suggests that for PNA-25-SDN and PNA-00/
25-SDN there are two phases or release (I and II). In phase I
the porosity introduced by PNA-25 could allow SDNs to be
released from the aggregate, giving a much larger dissolution
constant than the other formulations, Table 7. This is followed
by phase II where it appears that the remainder of the SDNs
are unable to diﬀuse out of the aggregate and instead are
released as drug molecules which then diﬀuse with a dis-
solution constant similar to the other formulations. PNA-00-
SDN and PNA-25-LPV only displayed one release phase.
PNA-00-SDN only contains PNA-00 microgel which forms a
much less porous structure, suggesting there is only release of
drug molecules rather than SDN’s. In PNA-25-LPV the lopinavir
drug was in the form of a micron-sized powder (see ESI
Fig. S10†), not as SDNs. Hence no two stage release is seen, as
the large powder particles are not able to diﬀuse through the
aggregate and instead only dissolved drug molecules are
released.
The burst release from the initial aggregation of the disk is
only 4.3% and 3.4% for PNA-00/25-SDN and PNA-00-SDN
respectively. The PNA-25-SDN nanocomposite was the only
Fig. 7 Release of LPV drug from aggregated microgel discs over 120
days; quantiﬁed by HPLC analysis. An SDN control without microgel,
‘Free SDN’, was performed. After 120 days the depot was dissolved in
acetonitrile for HPLC analysis to check remaining drug + amount
released = 100% (A) cumulative release (B) release rate, lines are guides
for the eye (C) application of the Higuchi model to the LPV release over
120 days.
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sample to show appreciable burst release of 33.1%. As seen in
the SEM/AFM analysis in Fig. 4 the PNA-25 microgel aggregate
was the most porous, therefore it is possible that the SDNs
near the surface of the aggregate were squeezed out rapidly
through the pores during the initial aggregation, leading to a
burst release. This theory is also supported by the concen-
tration of LPV obtained during the burst release, much higher
than the solubility of the hydrophobic drug lopinavir which
would only be possible if the drug was released in SDN form.
However, the water content of PNA-00/25-SDN nanocomposite
was also reasonably high at 56.4% (w/w) and may have pre-
sented porosity and yet very little burst release was found. This
diﬀerence could also be attributed to diﬀerent particle
packing; the opposite surface charges in PNA-00/25-SDN may
lead to attractive interactions between microgel particles
reducing the porosity of the material. This behaviour will be
further studied in our future work. The formulation PNA-25-
LPV, which contains the drug in powdered form, rather than
as an SDN, displayed the slowest release rate with total release
lower than all the SDN formulations, despite being loaded into
the most porous depot formed from PNA-25. Hence, loading
drug in SDN form allows the release rate from the depot to be
enhanced, likely due to the much greater surface area of the
SDNs assisting dissolution;72 or their amorphous nature,49
which aids in dissolution rate of drugs vs. crystalline drug
form.73 This behaviour potentially oﬀers an additional mech-
anism of controlling the rate of drug release from the nano-
composite. In powdered drug form the burst release is also
minimal at 0.5%, despite the SDNs having a 33.1% burst
release from the same PNA-25 microgel. This reinforces the
idea of porosity being linked to water content of the aggre-
gates, with small nanoparticulates releasing at a greater rate
than the powdered form of the drug.
Although the release rate was not clinically relevant for LPV
we have demonstrated sustained release and the potential for
the rate of release to be tuneable for the drug and it’s SDN
form. Hence, this system should be applicable to other more
clinically relevant poorly water-soluble drugs. These release
studies showed that the rate of release of dissolved drug mole-
cules can be tuned by blending microgels with diﬀerent
polymer composition, and by varying the form of the drug.
3.6 Cytotoxicity study
PNIPAm has been widely used as a potential material for drug
delivery and has been shown not to display cytotoxic properties
in numerous studies including PNIPAm in microgel form.74–76
Additionally, Kjøniksen et al. have revealed that even at a high
concentration PNIPAm microgels are not cytotoxic.46
The ATP, Fig. 8, and MTT (see ESI Fig. S11†) assays showed
that when MDCK-II cells were incubated with PNA-00 and
PNA-25 for 72 hours, at concentrations ranging from 0.04
mg ml−1 to 10 mg ml−1, no sign of cell toxicity could be
detected. The positive control rotenone was characterised by
reduced cell viability compared to the control at all tested con-
centrations (from 0.19 µM to 100 µM). It can be concluded
that the MTT assay could correctly detect reduction of mito-
chondrial activity in the presence of PNA-00 and PNA-25 and
lack of direct eﬀect on this cell function in the presence of
rotenone. The ATP assay could measure the cell viability by
measuring the luminescent signal given out when beetle luci-
ferin is oxidised to oxyluciferin in the presence of ATP
obtained from the cells after lysis. Considering the nature of
the MTT and ATP assay, other cytotoxic eﬀects cannot be dis-
missed; consequently, future investigations to support the
development of PNA-00 and PNA-25 clinical applications
should include a comprehensive evaluation of cellular,
immunological and tissue toxicities.
4. Conclusion
PNIPAm and PNIPAm-co-AlA microgels were found to provide a
long term sustained release of the hydrophobic drug LPV and
its SDN form. PNIPAm microgels could be formulated to
contain a nanoparticulate payload to form an injectable nano-
composite material in response to a dual stimulus of tempera-
ture and salt. The system overcomes some of the common pro-
blems associated with ISFIs that have previously been devel-
oped. For example, the formulation with drug was simple to
perform, it was easily injectable through a minimally invasive
hypodermic needle, showed minimal burst release, and mech-
anical stability throughout the release. Sustained release of
drug from the material was also maintained for a period of at
least 120 days. The potential to easily tune the release rate
from the system by adjusting the ratio of the two microgel
species PNA-00 and PNA-25, or enhance the release rate of the
drug by using the form of SDNs was also demonstrated. This
Table 7 Correlation coeﬃcient (Rc) and Higuchi dissolution constant
(kH)
Formulation
Phase I Phase II
Rc kH days
−0.5 Rc kH days
−0.5
PNA-25 0.994 5.25 0.993 1.16
PNA-00/25-SDN 0.999 6.33 0.966 2.34
PNA-00-SDN 0.999 3.05 — —
PNA-25-LPV 0.992 1.43 — —
Fig. 8 Cytotoxicity of microgels towards cells in ATP assay.
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drug delivery system should be applicable to other hydro-
phobic drugs, and cytotoxicity is not an issue.
This makes the system a suitable candidate as an ISFI for
hydrophobic drugs and SDNs, where injections could possibly
be given as infrequently as twice a year to improve adherence
rates in the treatment of long term and particularly chronic
conditions. The inflammation response at the depot site still
requires investigation. There is also the potential to release
multiple drugs as a combination therapy.
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